WO2013018018A1 - Combinaison antitumorale comprenant l'ombrabuline et le cétuximab, associée à une radiothérapie - Google Patents
Combinaison antitumorale comprenant l'ombrabuline et le cétuximab, associée à une radiothérapie Download PDFInfo
- Publication number
- WO2013018018A1 WO2013018018A1 PCT/IB2012/053881 IB2012053881W WO2013018018A1 WO 2013018018 A1 WO2013018018 A1 WO 2013018018A1 IB 2012053881 W IB2012053881 W IB 2012053881W WO 2013018018 A1 WO2013018018 A1 WO 2013018018A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cetuximab
- ombrabulin
- ave8062
- radiotherapy
- administration
- Prior art date
Links
- IXWNTLSTOZFSCM-YVACAVLKSA-N ombrabulin Chemical compound C1=C(NC(=O)[C@@H](N)CO)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 IXWNTLSTOZFSCM-YVACAVLKSA-N 0.000 title claims abstract description 117
- 229950003600 ombrabulin Drugs 0.000 title claims abstract description 117
- 238000001959 radiotherapy Methods 0.000 title claims abstract description 48
- 230000000259 anti-tumor effect Effects 0.000 title claims abstract description 19
- 229960005395 cetuximab Drugs 0.000 title claims description 70
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 85
- 150000003839 salts Chemical class 0.000 claims abstract description 15
- 238000011282 treatment Methods 0.000 claims description 20
- 239000003795 chemical substances by application Substances 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 15
- 238000009472 formulation Methods 0.000 claims description 14
- 201000011510 cancer Diseases 0.000 claims description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- 201000010536 head and neck cancer Diseases 0.000 claims description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical group CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 abstract 1
- 229960004316 cisplatin Drugs 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 238000002512 chemotherapy Methods 0.000 description 6
- 238000001990 intravenous administration Methods 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000005865 ionizing radiation Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- 239000004066 vascular targeting agent Substances 0.000 description 4
- 108060006698 EGF receptor Proteins 0.000 description 3
- 102000001301 EGF receptor Human genes 0.000 description 3
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 229940082789 erbitux Drugs 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000013421 nuclear magnetic resonance imaging Methods 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000012829 chemotherapy agent Substances 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- -1 cyclophosphamide Chemical compound 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 2
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- QSAMWSFELUCKOA-WAYWQWQTSA-N 2-methoxy-5-[(z)-2-(3,4,5-trimethoxyphenyl)ethenyl]aniline Chemical compound C1=C(N)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 QSAMWSFELUCKOA-WAYWQWQTSA-N 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 1
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 1
- 208000022120 Jeavons syndrome Diseases 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229940123237 Taxane Drugs 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 229940122803 Vinca alkaloid Drugs 0.000 description 1
- 229960002833 aflibercept Drugs 0.000 description 1
- 108010081667 aflibercept Proteins 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 229940100197 antimetabolite Drugs 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000006369 cell cycle progression Effects 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 229960000684 cytarabine Drugs 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000006274 endogenous ligand Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 150000003057 platinum Chemical class 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 229940063683 taxotere Drugs 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the present invention relates to a combination therapy for treating cancer, in particular involving solid tumours, implementing a coadministration of ombrabulin, of cetuximab and of radiotherapy.
- WO 2007/077309 describes the combination of AVE8062 and VEGF Trap (or aflibercept), an agent which prevents tumour angiogenesis.
- WO 2004/037258 describes the combination of AVE8062 and various antitumour agents chosen from taxanes, including taxol and taxotere, alkylating agents such as cyclophosphamide, or ifosfamide, antimetabolites such as 5-FU or cytarabine, epidophyllotoxin, antibiotics, including doxorubicin, and also vinca alkaloids.
- WO 2010/128259 describes an antitumour combination comprising AVE8062 and sorafenib.
- VDA tumour vascular disrupting agent
- RTKs receptor tyrosine kinases
- cetuximab can be combined with other anticancer treatments such as radiotherapy and platinum-salt-based chemotherapy.
- the invention relates to a combination therapy for treating cancer, in particular involving solid tumours.
- the invention relates more particularly to a pharmaceutical combination comprising ombrabulin or AVE8062 in the form of a base or in the form of a pharmaceutically acceptable salt, and cetuximab, for use thereof as an antitumour agent intended for patients who are also treated with radiotherapy, in particular suffering from cancers and even more particularly suffering from solid tumours.
- ombrabulin, of cetuximab and of radiotherapy can be separate, simultaneous or spread out over time.
- the invention also relates to the use of ombrabulin or AVE8062 and of cetuximab for preparing an antitumour combination intended for treating patients who are also treated with radiotherapy, in particular patients suffering from cancers and even more particularly suffering from solid tumours.
- ombrabulin or AVE 8062 and of cetuximab for preparing an antitumour combination intended to be administered in association, simultaneously, separately or spread out over time, with radiotherapy.
- ombrabulin or AVE8062 and of cetuximab for preparing a medicament intended to be used simultaneously, separately or spread out over time, with radiotherapy, for treating cancer and more particularly solid tumours.
- the present invention relates to a pharmaceutical combination
- a pharmaceutical combination comprising ombrabulin or AVE8062 in the form of a base or in the form of a pharmaceutically acceptable salt, and cetuximab, for separate administration, administration spread out over time or simultaneous administration to patients who are also treated with radiotherapy, in particular patients suffering from cancers and even more particularly suffering from solid tumours.
- the present invention relates to a pharmaceutical combination
- a pharmaceutical combination comprising ombrabulin or AVE8062 in the form of a base or in the form of a pharmaceutically acceptable salt, and cetuximab, for use thereof as an antitumour agent, said combination being administered in association with radiotherapy.
- the combination which, in the context of the present invention, means the combination of ombrabulin or AVE8062 in the form of a base or in the form of a pharmaceutically acceptable salt and of cetuximab, comprises an effective amount of ombrabulin or AVE8062 and an effective amount of cetuximab.
- the radiotherapy is also administered at an effective dose.
- the separate administration, simultaneous administration or administration spread out over time of a medicinal combination means that the elementary constituents of the combination, and in the present case, including the ionizing radiations, can be administered at the same time, each in one go at distinct moments, or repeatedly, or else at different moments, in particular during cycles.
- the elementary constituents can, in order to do this, be formulated as mixtures, only if they are administered simultaneously, or else formulated separately for the other administration schemes.
- Ombrabulin or AVE8062 can be in the form of a base or in the form of a pharmaceutically acceptable acid salt.
- salts mention may be made of the hydrochloride, acetate, phosphate or methanesulfonate.
- Ombrabulin or AVE8062 has the formula:
- tumour vascular disrupting agent or VDA
- ombrabulin or AVE8062 can be administered in the form of a base (cf. formula above) or in the form of a pharmaceutically acceptable acid salt, for example in the form of the hydrochloride, represented below:
- Cetuximab is sold under the brand Erbitux ® . It is a chimeric monoclonal antibody which binds specifically to the extracellular domain of the human epidermal growth factor receptor (EGFR). It is composed of the Fv region of a murine anti-EGFR antibody and of the human IgGl constant regions (heavy and kappa chains). It is produced by cell culture of a murine myeloma.
- EGFR epidermal growth factor receptor
- the EGFR signalling pathways are involved in the control of cell survival, of cell cycle progression, of angiogenesis, of migration, of cell invasion and of the metastatic potential of cells.
- Cetuximab blocks the binding of the endogenous ligands of the EGFR, resulting in an inhibition of the function of the receptor.
- said combination can be in the form of a unit pharmaceutical preparation.
- said combination can consist in combining ombrabulin or AVE8062 and cetuximab in the form of two pharmaceutical preparations.
- the combination can be in the form of a combination kit or product.
- the pharmaceutical combination of ombrabulin and cetuximab can in particular take the form of a kit comprising:
- the combination can be administered repeatedly over the course of several cycles according to a protocol which depends on the nature and on the stage of the cancer to be treated and also on the patient to be treated (age, weight, previous treatment(s), etc.).
- the protocol can be determined by any practitioner specializing in oncology.
- the present invention relates to a pharmaceutical kit, in particular intended for treating cancer and more particularly solid tumours, comprising: (i) a first galenical formulation comprising ombrabulin or AVE8062 in the form of a base or of a pharmaceutically acceptable salt,
- the two galenical formulations (i) and (ii) being intended to be administered separately, simultaneously or spread out over time with respect to one another, of use for a joint administration of radiotherapy, the two galenical formulations (i) and (ii) being intended to be administered independently of one another, separately, simultaneously or spread out over time with respect to said administration of radiotherapy.
- the present invention relates to a pharmaceutical kit, in particular intended for treating cancer and more particularly solid tumours, comprising:
- the two galenical formulations (i) and (ii) being intended to be administered separately, simultaneously or spread out over time with respect to one another, said kit being administered in association with radiotherapy, the radiotherapy being itself intended to be administered separately, simultaneously or spread out over time with said kit.
- Radiotherapy is a method of locoregional treatment of cancers, using radiation to destroy the cancer cells by blocking their ability to multiply.
- Radiotherapy in the context of the present invention, consists in particular of the therapeutic use of ionizing radiation.
- Said radiotherapy and the associated ionizing radiation are those commonly used and known to those skilled in the art.
- Radiotherapy includes in particular the use of ionizing radiation, for example ⁇ -rays, X-rays and/or radiation emanating from radioisotopes. In the context of the present invention, it is more particularly X-ray radiation.
- the combination may be intended to be administered to a patient over the course of a cycle that can range from 1 to 4 weeks, more particularly 3 weeks.
- the cycle defines the interval between the beginning and the end of an administration scheme for the combination in accordance with the present invention.
- this cycle comprises an administration of ombrabulin or AVE8062, and three administrations of cetuximab.
- the administration of the ombrabulin and of the first dose of cetuximab may be simultaneous or at different times.
- the first dose of cetuximab may be delayed by one or two days after the administration of ombrabulin, the taking of which starts the duration of the cycle.
- cetuximab can be administered in three intakes, with one week between intakes.
- the radiotherapy may, for its part, be administered in fractionated form during one or more cycles such as defined above.
- the radiotherapy may in particular be administered at a rate of one daily irradiation, 5 days out of 7, for 7 weeks.
- the administration mode may be the parenteral route and/or the oral route and depends on the galenical form used for the antitumour agent.
- the antitumour agent may be administered intravenously, as a bolus or prepared in an intravenous drip bag, with pharmaceutically acceptable vectors by means of various methods known to those skilled in the art.
- the ombrabulin or AVE8062 is administered parenterally, such as by intravenous administration, as a bolus or by drip, and the cetuximab is administered parenterally, such as the intravenous route.
- One galenical form of ombrabulin or AVE8062 which is suitable for the parenteral route is that in which the ombrabulin or AVE8062 is in solution in water.
- One galenical form of cetuximab which is suitable for the intravenous route is, for example, that sold under the brand Erbitux ® in the form of a drip solution.
- the invention relates to a combination as defined previously, suitable for parenteral administration, and more particularly suitable for administration of the ombrabulin or AVE8062 intravenously, as a bolus or by drip and for administration of the cetuximab intravenously.
- the doses of AVE8062 and of cetuximab administered each time to a patient depend on various parameters, such as the nature and stage of the cancer to be treated, and also on the patient to be treated (age, weight, previous treatment(s), etc.).
- the AVE8062 can be administered once every 3 weeks at a tolerated dose of between 5 and 60 mg/m 2 of body surface (dose defined for each administration).
- the cetuximab can be administered, for its part, at a tolerated dose of between 250 and 400 mg/m 2 of body surface (dose defined for each administration).
- the radiotherapy doses depend on the type of tumour and can range from 45 to more than 75 gray (Gy), more specifically from 50 to 60 Gy, over the total duration of the treatment.
- the doses may, for example, be 10 Gy per week at a rate of five sessions of 2 Gy per day.
- the combination can be effective in the treatment of cancers, more particularly of solid tumours in general, preferentially in the treatment of head and neck cancer, lung cancer, cervical cancer or stomach cancer.
- the present application also relates to a method for prevention or therapeutic treatment of cancers and more particularly solid tumours, consisting in administering to patients, in need thereof, an effective amount of ombrabulin or AVE8062, an effective amount of cetuximab and an effective dose of radiotherapy, it being possible for their administration to be carried out separately, simultaneously or spread out over time.
- an antitumour activity is declared for AT/AC ⁇ 40%.
- the antitumour activity on solid tumours is determined experimentally in the following way: the animals subjected to the experiment are NMRI female mice which are subcutaneously inoculated unilaterally with 3 million cells of the FaDu tumour line originating from a human hypopharyngeal tumour, on day 0. This tumour, representative of head and neck squamous cell carcinomas, is sensitive to cetuximab and to irradiation.
- the animals, bearing tumours having reached a tumour size previously defined and greater than 100 mg, are distributed in the various treatment and control groups, in such a way that the tumour size range is comparable from one group to the other.
- the chemotherapy begins from 3 to 22 days after the graft, depending on the type of tumour and the tumour size desired.
- the animals are observed and weighed every day.
- a dose which induces a weight loss of 20% or more on the day the weight loss is at a maximum (nadir - mean of the group) or a mortality of 10% or more is considered to be toxic.
- the tumours are measured two or three times per week until they reach approximately 2 g or until the animal dies if that occurs before the tumour reaches 2 g.
- the animals are autopsied when they are sacrificed.
- the ombrabulin or AVE8062 in hydrochloride form is formulated in water with 0.9% NaCl.
- the cetuximab is formulated in a calcium- and magnesium-free phosphate buffer, at pH 7.4.
- the locoregional radiotherapy is carried out at a dose rate of 0.35 Gy/min.
- the ombrabulin or AVE8062 was administered intravenously, at a sub-optimal dose, on days 15 and 19 following tumour implantation.
- the cetuximab was administered intraperitoneally, at a sub-optimal dose, on the same days.
- the animals were irradiated at a sub-optimal dose on days 15 and 19.
- the combination of the two chemotherapy agents is performed 5 hours apart (cetuximab administered first).
- the radiotherapy is performed 4 hours after the administration of the cetuximab.
- the animals receive the ombrabulin or AVE8062 one hour after irradiation.
- the loss of body weight is reported for each group on the day it reaches its nadir.
- the change in tumour weight in the treated group compared with the control group and also the median regression percentage are reported 7 days after the final treatment (D26) and the delay in reaching a target tumour weight of 1000 mg is calculated.
- the statistical studies compare the tumour volumes in the treated groups compared with the control group (for the irradiation alone), compared with the chemotherapy agents alone (for the combinations in doublet) or compared with the doublets (for the triple combination). The benefit of the combinations is evaluated over a period of 21 days after the end of the treatment (up to D40).
- Table I gives the experimental results of the study.
- the tumour doubling time was approximately 8 days.
- the median tumour weight at the beginning of the treatments was from 308 to 456 mg, the control having reached a tumour weight of 1000 mg 23.2 days after the tumour graft.
- the dose tested for AVE8062 is 36 mg/kg per injection, i.e. a total dose of 72 mg/kg. At this dose, AVE8062 is marginally active with a median %AT/AC of 37% and one partial regression (14% PR). The delay in growth compared with the control group is 4.8 days.
- Cetuximab is tested at the dose of 20 mg/kg per administration, i.e. a total dose of 40 mg/kg. At this dose, cetuximab is active with a median %AT/AC of 23.8%, no tumour regression (0% PR) and a delay in growth of 12.2 days.
- the irradiation at the dose of 3 Gy per session i.e. a total dose of 6 Gy, exhibits a marginal antitumour activity with a median %AT/AC of 36.8%, no tumour regression (0% PR) and a delay in growth of 7.0 days.
- AVE8062 combined with radiotherapy is highly active with a negative median % ⁇ / AC, a median tumour regression of 16%, and two partial tumour regressions (29%> PR).
- the delay in tumour growth in this group is 13.8 days.
- Cetuximab combined with radiotherapy is also highly active with a negative median %AT/AC of 0.1%, but no partial tumour regression (0% PR). The delay in tumour growth in this group is 13.3 days.
- AVE8062 combined with cetuximab is highly active with a negative median at %AT/AC and a median tumour regression of 42%. Five animals out of eight exhibit a partial regression (62% PR), none exhibiting complete tumour regression (0%) CR). The delay in tumour growth in this group reaches 18.2 days.
- the triple combination of AVE8062, cetuximab and irradiation shows the maximum antitumour activity in this study.
- the treatment is highly active with a negative median %AT/AC and a median tumour regression of 50%.
- Four animals out of seven exhibit a partial tumour regression (57% PR) and one animal exhibits complete tumour regression (14% CR).
- the delay in tumour growth in this group reaches 23.3 days.
- Table II shows the statistical analysis of the results of the study.
- the statistical analysis relating to the tumour volumes shows that:
- the irradiated group differs significantly from the control group (p ⁇ 0.0001), the double combinations of chemotherapy with radiotherapy are significantly different from the chemotherapies with agent alone (p ⁇ 0.0001),
- the combination of AVE8062 with cetuximab and radiotherapy induces partial tumour regressions, also observed in the double combinations containing AVE8062, and a complete tumour regression, only observed in this treatment group.
- the delay in growth for the triple combination is greater than that observed in the double combinations, making the triple combination the best arm of treatment in this study.
- the combination of AVE8062 with cetuximab and radiotherapy therefore confers a statistically significant therapeutic advantage in an experimental model of head and neck tumour.
- Table I Evaluation of AVE8062 in combination with cetuximab and radiotherapy on NMRI female mice bearing the FaDu head and neck squamous cell carcinoma: experimental results
- Agent related nadir day of % ⁇ / ⁇ 0 regression
- Median tumour weight at the beginning of treatments 308 - 456 mg.
- bwc body weight change
- ⁇ / ⁇ change in tumour weight in the treated group compared with the control group
- T-C delay in reaching the target tumour weight in the treated group compared with the control group
- IV intravenous route
- IP intraperitoneal route
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
La présente invention concerne une combinaison pharmaceutique antitumorale comprenant l'ombrabuline ou l'AVE8062, qui peut se présenter sous la forme d'une base ou d'un sel pharmaceutiquement acceptable, et le cisplatine, destinée à être utilisée comme agent antitumoral prévu pour des patients traités également par radiothérapie, souffrant plus particulièrement de cancers et même souffrant plus particulièrement de tumeurs solides.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1157044 | 2011-08-01 | ||
FR1157044A FR2978663A1 (fr) | 2011-08-01 | 2011-08-01 | Combinaison antitumorale comprenant l'ombrabuline et le cetuximab, associee a la radiotherapie |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013018018A1 true WO2013018018A1 (fr) | 2013-02-07 |
Family
ID=46832547
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2012/053881 WO2013018018A1 (fr) | 2011-08-01 | 2012-07-30 | Combinaison antitumorale comprenant l'ombrabuline et le cétuximab, associée à une radiothérapie |
Country Status (5)
Country | Link |
---|---|
AR (1) | AR087393A1 (fr) |
FR (1) | FR2978663A1 (fr) |
TW (1) | TW201315461A (fr) |
UY (1) | UY34233A (fr) |
WO (1) | WO2013018018A1 (fr) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0031085A2 (fr) | 1979-12-20 | 1981-07-01 | General Electric Company | Appareil de traitement de signaux à transfert de charges |
WO1999051246A1 (fr) | 1998-04-03 | 1999-10-14 | Ajinomoto Co., Inc. | Agents antitumoraux |
WO2003084919A2 (fr) | 2002-04-11 | 2003-10-16 | Aventis Pharma S.A. | Procedes de preparation de combretastatines |
EP1407784A1 (fr) | 2001-06-25 | 2004-04-14 | Ajinomoto Co., Inc. | Agents antitumoraux |
WO2004037258A1 (fr) | 2001-03-15 | 2004-05-06 | Aventis Pharma S.A. | Combinaison comprenant de la combretastatine et des agents anticancereux |
WO2007077309A1 (fr) | 2005-12-22 | 2007-07-12 | Aventis Pharma S.A. | Combinaison comprenant de la combretastatine et des agents anticancereux |
US20090209496A1 (en) * | 2008-02-15 | 2009-08-20 | David Chaplin | Methods and compositions for enhancing the efficacy of rtk inhibitors |
WO2010128259A1 (fr) | 2009-05-07 | 2010-11-11 | Sanofi-Aventis | Combinaison antitumorale comprenant l'ave8062 et le sorafenib |
-
2011
- 2011-08-01 FR FR1157044A patent/FR2978663A1/fr not_active Withdrawn
-
2012
- 2012-07-30 WO PCT/IB2012/053881 patent/WO2013018018A1/fr active Application Filing
- 2012-07-31 AR ARP120102782A patent/AR087393A1/es not_active Application Discontinuation
- 2012-08-01 TW TW101127821A patent/TW201315461A/zh unknown
- 2012-08-01 UY UY0001034233A patent/UY34233A/es not_active Application Discontinuation
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0031085A2 (fr) | 1979-12-20 | 1981-07-01 | General Electric Company | Appareil de traitement de signaux à transfert de charges |
WO1999051246A1 (fr) | 1998-04-03 | 1999-10-14 | Ajinomoto Co., Inc. | Agents antitumoraux |
WO2004037258A1 (fr) | 2001-03-15 | 2004-05-06 | Aventis Pharma S.A. | Combinaison comprenant de la combretastatine et des agents anticancereux |
EP1407784A1 (fr) | 2001-06-25 | 2004-04-14 | Ajinomoto Co., Inc. | Agents antitumoraux |
WO2003084919A2 (fr) | 2002-04-11 | 2003-10-16 | Aventis Pharma S.A. | Procedes de preparation de combretastatines |
WO2007077309A1 (fr) | 2005-12-22 | 2007-07-12 | Aventis Pharma S.A. | Combinaison comprenant de la combretastatine et des agents anticancereux |
US20090209496A1 (en) * | 2008-02-15 | 2009-08-20 | David Chaplin | Methods and compositions for enhancing the efficacy of rtk inhibitors |
WO2009103076A1 (fr) | 2008-02-15 | 2009-08-20 | Oxigene, Inc. | Méthodes et compositions pour améliorer l'efficacité des inhibiteurs des récepteurs tyrosine kinases (rtk) |
WO2010128259A1 (fr) | 2009-05-07 | 2010-11-11 | Sanofi-Aventis | Combinaison antitumorale comprenant l'ave8062 et le sorafenib |
Non-Patent Citations (6)
Title |
---|
"Pharmaceutical salts", J.PHARM.SCI., vol. 66, 1977, pages 1 - 19 |
BONNER JAMES A ET AL: "Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.", THE NEW ENGLAND JOURNAL OF MEDICINE 9 FEB 2006 LNKD- PUBMED:16467544, vol. 354, no. 6, 9 February 2006 (2006-02-09), pages 567 - 578, XP002680334, ISSN: 1533-4406 * |
CHARGARI C ET AL: "Etat des lieux des associations chimioradiotherapeutiques et place potentielle des therapies ciblees dans les cancers bronchiques non a petites cellules", CANCER RADIOTHERAPIE, ELSEVIER, PARIS, FR, vol. 13, no. 2, 1 April 2009 (2009-04-01), pages 114 - 122, XP025977246, ISSN: 1278-3218, [retrieved on 20090120], DOI: 10.1016/J.CANRAD.2008.08.273 * |
MAGNE ET AL: "Donnees actuelles des associations chimioradiotherapeutiques et place potentielle des therapies ciblees dans les cancers du col uterin", CANCER RADIOTHERAPIE, ELSEVIER, PARIS, FR, vol. 12, no. 1, 15 January 2008 (2008-01-15), pages 31 - 36, XP022510158, ISSN: 1278-3218, DOI: 10.1016/J.CANRAD.2007.11.008 * |
PATTERSON ET AL: "Vascular Damaging Agents", CLINICAL ONCOLOGY, W.B. SAUNDERS, AMSTERDAM, NL, vol. 19, no. 6, 2 July 2007 (2007-07-02), pages 443 - 456, XP022137687, ISSN: 0936-6555, DOI: 10.1016/J.CLON.2007.03.014 * |
SHIBUYA ET AL: "Targeted Therapy Against VEGFR and EGFR With ZD6474 Enhances the Therapeutic Efficacy of Irradiation in an Orthotopic Model of Human Non-Small-Cell Lung Cancer", INTERNATIONAL JOURNAL OF RADIATION: ONCOLOGY BIOLOGY PHYSICS, PERGAMON PRESS, USA, vol. 69, no. 5, 20 November 2007 (2007-11-20), pages 1534 - 1543, XP022354203, ISSN: 0360-3016, DOI: 10.1016/J.IJROBP.2007.07.2350 * |
Also Published As
Publication number | Publication date |
---|---|
UY34233A (es) | 2013-02-28 |
AR087393A1 (es) | 2014-03-19 |
TW201315461A (zh) | 2013-04-16 |
FR2978663A1 (fr) | 2013-02-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111065411B (zh) | Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途 | |
CN111132696B (zh) | Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途 | |
TW201024310A (en) | Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine | |
WO2014142220A1 (fr) | Agent antitumoral | |
JP2019517549A5 (fr) | ||
JP2019508433A (ja) | Liv1−adc及び化学療法剤を用いた併用療法 | |
EP3445366A1 (fr) | Méthode de traitement du cancer du foie | |
JP2009536956A (ja) | 抗癌治療法 | |
CN102438608A (zh) | 包含ave8062和索拉非尼的抗肿瘤组合 | |
JP2017537927A5 (fr) | ||
CN112043831A (zh) | 用于联合治疗乳腺癌的喹啉类化合物 | |
KR101226631B1 (ko) | 항암 치료 방법 | |
US20200237779A1 (en) | Combination therapy with a bet inhibitor and a bcl-2 inhibitor | |
TW201306833A (zh) | 包含康布列塔司他汀(combretastatins)族衍生物及西妥昔單抗(cetuximab)之組合 | |
WO2013018018A1 (fr) | Combinaison antitumorale comprenant l'ombrabuline et le cétuximab, associée à une radiothérapie | |
WO2023134706A1 (fr) | Utilisation combinée d'un conjugué anticorps anti-trop-2-médicament et d'autres agents thérapeutiques | |
JPWO2020030977A5 (fr) | ||
WO2013018017A1 (fr) | Combinaison antitumorale comprenant de l'ombrabuline et du cisplatine, associée à la radiothérapie | |
EP1599210A1 (fr) | Traitement combine comprenant un derive d'indolopyrrolocarbazole et un autre agent antitumoral | |
WO2025103377A1 (fr) | Méthode de traitement du cancer par l'intermédiaire d'un conjugué anticorps-médicament anti-b7h3 | |
Kim et al. | CO26. Results of a phase 1/2 study for KW-0761, a monoclonal antibody directed against CC chemokine receptor type 4 (CCR4), in CTCL patients | |
NZ788180A (en) | Combination therapy with notch and pd-1 or pd-l1 inhibitors | |
Citterio et al. | 1228 Phase I study of NGR-hTNF, a vascular targeting agent (VTA), in combination withcisplatin in refractory patients (pts) with solid tumours | |
Chew et al. | 1229 A phase I study of continuous and intermittent schedules of lapatinib in combination with vinorelbine in solid tumors | |
Trarbach et al. | 1230 Cediranib (an oral, highly potent VEGF signalling inhibitor) in combination with saracatinib (AZD0530; a potent, selective Src inhibitor): a phase I open-label study in patients with advanced solid tumours |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12758639 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 12758639 Country of ref document: EP Kind code of ref document: A1 |